HIF1A and pulmonary fibrosis: The promotion of FAO, inhibition of glycolysis and HIF‐1α reduce ECM production and promote ECM degradation, ultimately impeding the progression of fibrosis and providing therapeutic relief for established pulmonary fibrosis.